Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharmaceutical intelligence for consultancies

Focus on your clients and expand your business opportunities. We’ll help you build a complete picture of the rapidly changing pharmaceutical market with our insight and expertise.

Your trusted pharma partner

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. Pharma Intelligence will help you make smart decisions and stay ahead of a fast changing market.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our wide range of solutions cover early phase, clinical R&D, portfolio and strategy, regulatory and commercial planning and analysis.

We cover the life sciences business from drug and device discovery and development to regulatory approval, and drug reimbursement to lifecycle management. And we give you access to past, current and future trends and analysis.

How it helps

Whether you’re working on your next business pitch, engaging on a project for an existing client or working on due diligence for a proposed merger or acquisition; our pharmaceutical intelligence helps you meet the demands of dynamic markets and changing customer needs, with:

Expert analysis of key pharma sectors
In-depth knowledge from drug discovery to market access
Global coverage including digital health, R&D, and emerging markets
Precise analysis and data
Customized reports

Our unique strengths

Understand your clients’ world

Gain a comprehensive understanding of the global pharma market with our complete coverage.

Stay on top of the details

We’ll keep you in touch with complex regulatory and pricing and reimbursement issues.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking drug pipelines, patent expiration and commercial activities influencing the landscape.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

Pink Sheet

The Tricky Task Of Bringing Smaller EU Countries Into The Fold

By Maureen Kenny 12 Sep 2018

Clusters of excellence, competition as well as co-operation, Brexit, and aiming high. Danish Medicines Agency head Thomas Senderovitz talks national agencies and engagement in an interview with the Pink Sheet.

Topic Brexit Drug development landscape Drug approval

View article
Pink Sheet

Clearer Purpose And Direction Needed For EU Agency Heads Network

By Maureen Kenny 12 Sep 2018

Thomas Senderovitz will chair the management group of the EU Heads of Medicines Agencies for at least the next two years. The Danish regulator tells the Pink Sheet of his big plans for the network.

Topic Business strategies Company analysis

View article
Pink Sheet

Brexit Likely To Force Refocusing Of Ambitious EU Network Strategy

By Maureen Kenny 12 Sep 2018

The European Medicines Agency and drug regulators throughout the EU are having to invest huge amounts of time and effort in dealing with the fall-out from Brexit - and it hasn't even happened yet. Plans for working together on bigger issues agreed on a few years ago will likely have to change, senior regulator Thomas Senderovitz tells the Pink Sheet.

Topic Brexit Business strategies

View article
Pink Sheet

Big Data In Medicines Regulation Will Need ‘Considerable Change In Mindset’

By Maureen Kenny 12 Sep 2018

Changing mindsets, technologies outpacing regulatory frameworks, intense international collaboration, and the future of the randomized controlled clinical trial. Big data is forcing us to think big, senior European regulator Thomas Senderovitz tells the Pink Sheet.

Topic Brexit Business strategies

View article
Scrip

Tech Transfer Roundup: How To Protect Downstream Rights

By Joseph Haas 12 Sep 2018

A review of tech transfer deals over 10 years shows that licensees often protect their value positions to limit royalties paid out to licensors. Meanwhile, licensors often protect their future rights with language recognizing that additional parties may be involved in producing a final product.

Topic Digital Health

View article
Scrip

Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit

By Mandy Jackson 12 Sep 2018

Despite several new entrants to the multiple myeloma market, Datamonitor Healthcare forecasts that drug sales between 2017 and 2026 will peak in 2022 when Revlimid generics hit the market. J&J's Darzalex will become the new best-seller, but generate a fraction of Revlimid's sales.

Topic Cancer Drug development landscape

View article
Datamonitor Healthcare

Neuropathic Pain Market and Forecast Analysis to 2026

By Nicola Sawalhi-Leckenby 07 Sep 2018

Big changes are coming to the neuropathic pain market – are you prepared? Take a look at the projected neuropathic pain drug sales for the US, Japan, and five EU nations with the latest infographic from Datamonitor Healthcare. This snapshot view of the future of the neuropathic pain market is packed with data from the full Datamonitor Healthcare Neuropathic Pain Disease Coverage report.

View infographic
Pink Sheet

Kymriah: England Becomes First In Europe To Say Yes To CAR-T

By Neena Brizmohun 06 Sep 2018

A new deal between Novartis and England’s National Health Service is one of the fastest funding approvals in the 70-year history of the NHS.

Topic Cancer

View article
Scrip

INFOGRAPHIC: Patent Losses Characterize Japan's Challenging Pharma Future

By Jo Shorthouse 06 Sep 2018

Although 10 of Japan’s largest pharma companies look set to add $11bn in revenues over the next nine years, a CAGR of only 1% reflects an expected $4.8bn in patent expiries, leaving Japanese pharma heads relying on innovation for the next phase of the region’s major wins.

Topic Business strategies

View article
Scrip

Art Of War: Why Pharma Must Do Digital Dance In China

By Brian Yang 06 Sep 2018

“Winning the war without fighting. Using five types of fire attacks.” Sounds familiar? Sun Tzu's 2,000 year-old wisdom on the art of war is echoing down the ages, and winning in China today means that pharma needs to embrace a digital strategy more than ever before.

Topic Digital Health

View article
Scrip

Chindia Generics: A Dream or Reality?

By Brian Yang 30 Aug 2018

Meeting and greeting is necessary, as is the right form of partnership and getting everyone on board. But as Indian drug makers learn the ropes of entering the complex Chinese market, the seemingly natural fit may still have a long way to go.

Topic Business strategies

View article
Scrip

Shire Could Reclaim HAE Prophylaxis Market From CSL Behring

By Joseph Haas 30 Aug 2018

Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.

Topic FDA

View article
Pink Sheet

US FDA To Withdraw Pain Drug Guidance As Part Of Response To Opioid Epidemic

By Nielsen Hobbs 30 Aug 2018

"At least four" guidances will replace it, Commissioner Gottlieb notes in frank update which states "I don’t want to look back ten years from now and wish there were more policies we had pursued, or more steps we had taken, to stop the advance of this crisis."

Topic FDA

View article
Datamonitor Healthcare

Meningococcal Vaccines Forecast Infographic

By Karolina Kujawa 28 Aug 2018

Over 1.2 million cases of bacterial meningitis are estimated to occur worldwide each year. If not treated promptly, up to half of those cases will be fatal. This infographic from Datamonitor Healthcare provides a snapshot of the meningococcal vaccines market in the US and five major EU markets. What does the meningococcal vaccines market have in store and how will it affect your business? Download now.

Topic Vaccines

View infographic
Datamonitor Healthcare

Epidiolex and Epilepsy - big changes for medical marijuana

By Stephanie Yip 28 Aug 2018

With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

Topic Drug approval

View white paper

Latest headlines

Scrip

19 Sep 2018

Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC

Link
Scrip

19 Sep 2018

ICON CEO: CROs Must Be Aware Of Threat Posed By Big Tech

Link
Scrip

19 Sep 2018

Executives On The Move: New CEOs Vaxil Bio and Akero Therapeutics, with Some Big Pharma Execs Joining Smaller Companies

Link
Pink Sheet

18 Sep 2018

Biosimilar Sponsors: We Need To Do A Better Job Educating Physicians And Patients

Link
Pink Sheet

18 Sep 2018

Northern Ireland Improves Access To Cancer Drugs Fund Treatments

Link
Pink Sheet

18 Sep 2018

Repeated Questions Prompt EMA To Reconsider Guidance On Neonates

Link
Pink Sheet

18 Sep 2018

Ukraine To Start Disclosing Clinical Trial Results

Link
Scrip

18 Sep 2018

Tildrakizumab Set For Europe Debut - Can It Make A Dent?

Link
Pink Sheet

18 Sep 2018

AbbVie Deployed Nurses As 'Runners And Cappers' In Humira Kickback Scheme, Suit Alleges

Link
Scrip

18 Sep 2018

Novo Nordisk Cuts 400 Jobs In R&D Reshuffle As It Broadens Its Horizons

Link
Scrip

18 Sep 2018

Viking’s Liver Fat Reduction Data Portend A New Competitor In NASH

Link
Scrip

18 Sep 2018

Pfizer Eyes First-To-Market Opportunity In Alopecia

Link
Pink Sheet

18 Sep 2018

Cigna Acquisition Of Express Scripts 'Unlikely' To Harm Competition Because It's Vertical, DOJ Concludes

Link
Scrip

18 Sep 2018

Boehringer Ingelheim Is Getting Bets In Early In IO Space

Link
Scrip

18 Sep 2018

Assessing Artios: $83m Series B, Big-Name Investors, Nothing In The Clinic

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Pharmaceutical intelligence for consultancies

Your trusted pharma partner

Our unique strengths

Understand your clients’ world

Stay on top of the details

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product List

Thought leadership

Awareness

Lead generation

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Pharma Report Store